Hemodynamic basis for the acute cardiac effects of troglitazone in isolated perfused rat hearts

Diabetes

Volumn 48, Issue 3, 1999, Pages 609-615

  Shimoyama, Masaki ^a   Ogino, Kazuhide ^a   Tanaka, Yasushi ^a   Ikeda, Tadasu ^a   Hisatome, Ichiro ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADRENERGIC RECEPTOR; CALCIUM CHANNEL; TROGLITAZONE;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DRUG EFFECT; DRUG SCREENING; HEART CONTRACTION; HEART HEMODYNAMICS; INOTROPISM; ISOLATED HEART; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0032972793     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.48.3.609     Document Type: Article

References (35)

1. Garcia M, McNamara P, Gordon T, Kannel W: Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study. Diabetes 23:105-111, 1974
2. Kannel W, McGee D: Diabetes and cardiovascular risk factors: the Framingham study. Circulation 59:8-13, 1979
3. Reaven G: Pathophysiology of insulin resistance in human disease. Physiol Rev 75:473-486, 1995
4. Gerich J: Oral hypoglycemic agents. N Engl J Med 321:1231-1245, 1989
5. Whitecomb R, Saltiel A: Oncologic, endocrine and metabolic: thiazolidinediones. Exp Opin Invest Drug 4:1299-1309, 1995
6. Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I, Horikoshi H: Characterization of new oral antidiabetic agent CS-045. Diabetes 37:1549-1558, 1988
7. Yoshioka T, Fujita T, Kanai T, Aizawa Y, Kurumada T, Hasegawa K, Horikoshi H: Studies on hindered phenols and analogues. I. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation. J Med Chem 32:421-428, 1989
8. Ciaraldi T, Glimore A, Olefsky J, Goldberg M, Heidenreich K: In vitro studies on the action of CS-045, a new antidiabetic agent. Metabolism 39:1056-1062, 1990
9. Yoshioka S, Nishino H, Shiraki T, Ikeda K, Koike H, Okumo A, Wada M, Fujiwara T, Horikoshi H: Antihypertensive effects of CS-045 treatment in obese Zucker rats. Metabolism 42:75-80, 1993
10. Suter S, Nolan J, Wallance P, Gumbiner B, Olefsky J: Metabolic effects of a new oral hypoglycemic agent, CS-045, in non-insulin dependent diabetic subjects. Diabetes Care 15:193-203, 1992
11. Nolan J, Ludvik B, Beerdsen P, Joyce M, Olefsly J: Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 331:1188-1193, 1994
12. Kuzuya T, Iwamoto Y, Kosaka K, Tanabe K, Yamanouchi T, Kasuga M, Kajinuma H, Akanuma Y, Yoshida S, Shigeta Y, Baba S: A pilot clinical trial of a new oral hypoglycemic agent, CS-045, in patients with non-insulin dependent diabetes mellitus. Diabetes Res Clin Pract 11:147-154, 1994
13. Ogihara T, Rakugi H, Ikegami H, Mikami H, Masuo K: Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens 8:316-320, 1995
14. Pershadsingh H, Szollosi J, Benson S, Hyun W, Feuerstein B, Kurtz T: Effects of ciglitazone on blood pressure and intracellular calcium metabolism. Hypertension 21:1020-1023, 1993
15. Lee M, Miles P, Khoursheed M, Gao K, Moossa A, Olefsky J: Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat. Diabetes 43:1435-1439, 1994
16. Buchanan T, Meehan W, Jeng Y, Yang D, Chan T, Nadler J, Scott S, Rude R, Hsueh W: Blood pressure lowering by pioglitazone: evidence for a direct vascular effect. J Clin Invest 96:354-360, 1995
17. Kaufman L, Peterson M, DeGrange L. Pioglitazone attenuates diet-induced hypertension in rats. Metabolism 44:1105-1109, 1995
18. Kotchen T, Zhang H, Covelli M, Blehschmidt N: Insulin resistance and blood pressure in Dahl rats and in one-kidney, one-clip hypertensive rats. Am J Physiol 261:E692-E697, 1991
19. Zhang F, Sowers J, Ram J, Standley P, Peuler J: Effects of pioglitazone on calcium channels in vascular smooth muscle. Hypertension 24:170-175, 1994
20. Bähr M, Spelleken M, Beck M, von Holtey M, Kiehm R, Eckel J: Acute and chronic effects of troglitazone (CS-045) on isolated rat ventricular cardiomyocytes. Diabetologia 39:766-774, 1996
21. Shimabukuro M, Higa S, Shinzato T, Nagamine F, Komiya I, Takasu N: Cardioprotective effects of troglitazone in streptozotocin-induced diabetic rats. Metabolism 45:1168-1173, 1996
22. Ghazzi M, Perez J, Antonucci T, Driscoll J, Huang S, Faja B, The Troglitazone Study Group, Whitcomb R: Cardiac and glycemic benefits of troglitazone treatment in NIDDM. Diabetes 46:433-439, 1997
23. Ogino K, Burkhoff D, Bilezikian JP: The hemodynamic basis for the cardiac effects of parathyroid hormone (PTH) and PTH-related protein. Endocrinology 136:3024-3030, 1995
24. Kemnitz J, Elson D, Roecker E, Baum S, Bergman R, Meglasson M: Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels, and lowers blood pressure in obese, insulin-resistant rhesus monkeys. Diabetes 43:204-211, 1994
25. Stout R: Insulin and atheroma: 29-yr perspective. Diabetes Care 13:631-654, 1990
26. Kotchen T, Zhang H, Dubey R, Reddy S: Increasing insulin sensitivity attenuates hypertension (Abstract). Hypertension 20 (Suppl.):410, 1992
27. Kotchen T, Zhang H, Reddy S, Hoffmann R: Effects of pioglitazone on vascular reactivity in vivo and in vitro. Am J Physiol 270:R660-R666, 1996
28. Ren J, Dominguez L, Sowers J, Davidoff A: Troglitazone attenuates high-glucose-induced abnormalities in relexation and intracellular calcium in rat ventricular myocytes. Diabetes 45:1822-1825, 1996
29. 2+]. J Hypertens 15:269-274, 1997
30. Collier A, Wilson R, Bradley H, Thomson J, Small M: Free radical damage in type II diabetes. Diabet Med 7:27-30, 1990
31. Hess M, Okabe E, Kontos H: Proton and free oxygen radical interaction with the calcium transport system of cardiac sarcoplasmic reticulum. J Mol Cell Cardiol 13:767-772, 1981
32. 2+ pump activity by oxygen free radicals. Am J Physiol 256:H368-H374, 1989
33. Inoue I, Katayama S, Takahashi K, Negishi K, Miyazaki T, Sonoda M, Komada T: Troglitazone has a scavenging effect on reactive oxygen species. Biochem Biophys Res Commun 235:113-116, 1997
34. Walker A, Naderali E, Chattington P, Buckingham R, Williams G: Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro. Diabetes 47:810-814, 1998
35. Saku K, Zhang B, Ohta T, Arakawa K: Troglitazone lowers blood pressure and enhances insulin sensitivity in Watanabe heritable hyperlipidemic rabbits. Am J Hypertens 10:1027-1033, 1997